With one of the largest populations in Europe (approximately 66 million people) the United Kingdom (UK) is an important priority for Market Access for pharma, biotech and medtech firms. Recognized for its well-established healthcare system, the National Health Service (NHS), and HTA processes run by HTA bodies such as NICE, the UK provides universal coverage and broad access to healthcare services. Our agency Justin Stindt Consultants is specialized in facilitating Market Access in the United Kingdom and can help your company navigate UK Market Access.
Market Access UK – Essential to access one of the largest EU markets for pharma, biotech and medtech firms
The decentralized nature of the UK healthcare system implies timelines for achieving reimbursement and formulary listing may vary. There are several HTA bodies, the best known being the National Institute for Health and Care Excellence (NICE) responsible for England. For Scotland the SMC (Scottish Medicines Consortium) issues guidance, while for Wales the AWMSG (All Wales Medicines Strategy Group) performs HTA unless the NICE guideline is adopted.
NICE and SMC offer confidential scientific advice services that allow companies to seek early feedback on their development plans for medicines, medical devices, or diagnostics. This service aims to help companies design robust and relevant clinical trials and development programs, improving the chances of successful HTA submissions later on. For more information, visit our Health Technology Appraisal scientific advice discussions in the UK.
Understanding Cost-Effectiveness in UK Drug Market Access: QALY-based Assessments and Pricing Strategies”
Cost-effectiveness / Cost-utility is the key determinant in the UK pricing & reimbursement landscape and costly drugs usually enter the market through various commercial arrangements. Cost-utility assessments conducted in the UK are based on economic models which assess quality-adjusted life years (QALY) and cost. NICE now applies different cost-effectiveness thresholds based on the setting including a severity of disease modifier. For more information visit our P&R submissions in the UK.
Besides the standard HTA processes, the UK also provides funding opportunities for effective yet expensive drugs through the Cancer Drugs Fund (CDF). For more information visit our Pricing & Reimbursement pathways in the UK.
Justin Stindt Consultants is your consulting agency to support you with Market Access in the UK
Justin Stindt Consultants is your consulting firm with experts who have extensive experience in Market Access in the United Kingdom. Our consultancy has helped many clients by engaging NICE and SMC for scientific advice meetings and develop HTA dossiers.
As a service provider, our consultants also support patient access scheme negotiations. For medical devices and digital health apps, our agency supports dossiers and negotiations. Many of our consulting firm’s clients have found the UK to be a key place to start for Market Access in Europe and decided to enlist our agency as a partner of choice given our footprint and experience in the UK market.
Contact our experts today to learn how our agency can tailor our services to meet your unique needs to enable Market Access in the UK.
Market access services for pharmaceutical and biotech products in United-Kingdom
Case studies for UK market
- Support entire French Market Access process
- ATU Feasibility Assessment
- HAS early dialogue meeting
